secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vitro Biopharma, Inc. (—)
CIK:        0000793171
Form:       8-K
Filed at:   2023-07-07T23:59:59+00:00
Accession:  0001493152-23-023989
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vitro Biopharma executes 1-for-26 reverse stock split to meet NYSE American listing standards
--------------------------------------------------------------------------------

- Reverse stock split effective July 6, 2023; authorized shares reduced from 500M to ~19.23M.
- Outstanding shares cut from ~115.2M to ~4.4M; fractional shares cashed out or rounded up.
- Split intended to satisfy NYSE American initial listing requirements; expects ticker "VTRO".
- Articles amended to require 66-2/3% supermajority vote for director removal and limit special meetings.
- New bylaws include advance notice for shareholder nominations and plurality voting for directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/793171/000149315223023989/0001493152-23-023989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/793171/000149315223023989/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-023989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer